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creativecommons.org/dence and progression of cognitive decline in Chinese elderly, with the operational procedures and
diagnostic criteria similar to cohort studies in developed countries.
Methods: We prospectively evaluated 362 individuals with mild cognitive impairment (MCI) diag-
nosed at baseline through a clinical and neuropsychological interview. Diagnoses of dementia and
MCI were made using standard criteria via consensus diagnosis.
Results: The conversion rate to dementia was 6.0 per 100 person-years, while the reversion rate to
cognitive normal was 7.8 per 100 person-years. Amnestic MCI multiple domains was the most risky
type for dementia (conversion rate: 14.2 per 100 person-years). Older age (hazard ratio [HR]5 1.09),
apolipoprotein E (APOE ε4) (HR 5 2.15), and low MMSE score (HR 5 1.18) were predictors for
dementia.
Discussion: Approximately 6% of elderly with MCI progress to dementia annually. Prospective
studies are needed to further examine risk and protective predictors and to seek proper interventions
for cognitive decline.
 2016 Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords: Mild cognitive impairment; Progression; Dementia; Conversion; prospective study; Aging; Risk factor1. Introduction
Mild cognitive impairment (MCI) is an intermediate state
between dementia and normal cognitive aging. The defini-
tion was later expanded to include other cognitive domains,
with the expectation that the initial pattern of impairment
predicted various diagnostic outcomes. MCI could provide
important information about the population at risk for
becoming demented. It is also a stage at which intervention
could be effective in reducing conversion to dementia [1–3].
Over the last 20 years, most published data of MCI pro-
gression are from Caucasians. A review of cohort studiesre no conflicts of interest.
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licenses/by-nc-nd/4.0/).published before 2002 estimated the annualized conversion
rate at approximately 10%, whereas a lower estimate of
7% was reported in a review of selected studies published
before October 2008 [4,5]. A recent systematic review
summarized published estimates for conversion from MCI
or amnestic MCI (aMCI) to Alzheimer’s dementia (AD)
and indicated that annual conversion rates ranged from
7.5% to 16.5% per person-year for hospital-based studies
and from 5.4% to 11.5% per person-year for community
samples [6]. The Alzheimer’s Disease Neuroimaging Initia-
tive study reported that patients with MCI progressed to AD
at a rate of 16.5% per year and regressed to normal at a rate
of 8% across a 12-month period [7]. Data from the Asian
population have just been reported in recent 2 years in
very limited studies, including two studies in Chinese and
one study in Arabic population, with the data varyingation. This is an open access article under the CC BY-NC-ND license (http://
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to dementia [8–10]. The substantial variation in the data of
MCI progression has been considered to be due to
differences in detection procedures, implementation of
MCI diagnostic criteria, and demographic characteristics
of the source populations. Fewer community-based studies
reported the progression for MCI subtypes [11–14].
China’s population accounts for 21% of the world popu-
lation and 1/3 of the Asian population. The number of people
aged 60 years or more reached 212 million at the end of
2014, which made up 15.5% of the total population [15].
Older population in China will likely swell to 330 million
or a quarter of its total population by 2050 [16]. Identifying
the MCI progression in Chinese population is crucial for as-
sessments of potential disease burden and therefore the need
for interventions to prevent or slow progression of decline to
dementia. Additionally, the data can be used to fill the gap of
the data shortage in the Asian region.
In 2011, we established a community-based study: the
Shanghai Aging Study, to investigate the prevalence, inci-
dence, and progression of cognitive decline in Chinese
elderly. Its baseline survey detected the prevalence of MCI
with clinical and neuropsychological evaluations of all indi-
viduals aged 60 years or older residing in a geographically
defined urban community of Shanghai [17,18]. As its
second wave, this study aimed to explore the progression
and predictors of MCI and its subtypes, through a
prospective follow-up in this community-based cohort.2. Methods
2.1. Ethics statement
The present study was approved by the Medical Ethics
Committee of Huashan Hospital, Fudan University,
Shanghai, China. All participants or their legally acceptable
representative have provided their written informed consent.
2.2. Study cohort with MCI
From January 1, 2010 through Sep 30, 2011, we conduct-
ed in-person interviews and clinical examinations for 3141
registered residents aged 60 years or older in Jingansi com-
munity in downtown Shanghai, China. We diagnosed 601 in-
dividuals with MCI among 2985 nondemented individuals
and demonstrated the MCI prevalence of 20% [17]. In the
later 3 months, we continued the clinical interview and
diagnosed additional 54 individuals with MCI. Thus, we
established a cohort with 655 individuals with MCI in the
Shanghai Aging Study.
2.3. Baseline characteristics of MCI cohort
At the baseline, demographic, lifestyle characteristics, and
medical histories of the participants were collected via an
interviewer-administered questionnaire, consisting of the
following measures: birth date, gender, education year andlevel, cigarette smoking, alcohol consumption, physician-
diagnosed hypertension, diabetes, stroke, and heart disease.
Apolipoprotein E (APOE) genotyping was conducted by the
TaqMan SNP method. The presence of at least one ε4 allele
was treated as being APOE ε4 positive. Detailed clinical and
neuropsychological assessments and diagnosis procedures
were described in the previous report of MCI prevalence [17].2.4. Follow-up procedure
From March 1, 2014 to Sep 30, 2015, we conducted a
follow-up study for this MCI cohort as the second wave of
the Shanghai Aging Study. A research coordinator contacted
all the individuals with MCI based on their contact informa-
tion recorded at the baseline survey. Individuals were
considered ineligible if they (1) were deceased; (2) had
moved from the original resident place; and (3) were
suffering with severe mental disorder, impairment of vision,
hearing or speaking and were not able to cooperate with clin-
ical interview and neuropsychological tests. For those
eligible individuals, an appointment for a clinical interview
(either at Huashan Hospital, or at their homes) was made af-
ter they agreed to participate. Participants were reminded of
the evaluation by a telephone call 1 day before it was sched-
uled. For those deceased individuals, the cause and date of
death were provided by their family members via the tele-
phone call and confirmed by the death certificates from the
Center of Disease Control.2.5. Interview at the follow-up
At the face-to-face interview, participants were firstly
asked for their cognitive complaints, which they, their proxy,
or a nurse or physician indicated that they had problems with
memory or thinking. Also, the time and hospital name were
recorded if the individual was diagnosed as dementia by neu-
rologists at other hospitals. Participants were measured the
Lawton and Brody Activity of Daily Living (ADL) scale,
to elicit physical self-maintenance and instrumental activ-
ities of daily living. Functionally intact were considered
for whose ADL scorewas over 16 [19]. Participants who suf-
fered with newly onset of hypertension, diabetes mellitus,
stroke, and heart disease were examined and confirmed
from the medical records.
Cognitive function of participants was evaluated by using
the neuropsychological batteries which were used at the
baseline survey. For participants with 6 or more years of
formal education, the battery comprised the Mini-Mental
State Examination (MMSE), Conflicting Instructions Task,
Stick Test, Modified Common Objects Sorting Test, Audi-
tory Verbal Learning Test, and Trail-making Test. For partic-
ipants with,6 years of education, the battery comprised the
MMSE, Conflicting Instructions Task, Stick Test, Modified
Common Objects Sorting Test, modified Fuld Object Mem-
ory Evaluation, and Renminbi Test. The battery was admin-
istered in Chinese by certified study psychometrists within
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were described elsewhere [17].2.6. Consensus diagnosis
Neurologists and neuropsychologists in our study group
(D.D., Q.Z., Q.G., and Z.H.) reviewed the medical and neu-
ropsychological data and reached a consensus regarding the
presence or absence of dementia using DSM-IV criteria
[20]. Only those who were not diagnosed with dementia
were considered for a diagnosis of MCI, which was defined
according to Petersen’s criteria [21]: (1) cognitive concern or
complaint by the subject, informant, nurse, or physician,
with CDR 5 0.5; (2) objective impairment in at least one
cognitive domain based on performance 1.5 standard devia-
tion (SD) below the mean using the norms obtained in the pi-
lot study; (3) essentially normal functional activities
(determined from the CDR and the ADL evaluations); and
(4) absence of dementia (DSM-IV).
Based on cognitive test scores, participants diagnosed
with MCI were placed into different groups characterizing
their cognitive deficits: (1) amnestic MCI single domain
(aMCI-SD: a deficit on at least 1 of the memory tests was
required with no deficit in other domains); (2) amnestic
MCI multiple domains (aMCI-MD: at least 1 deficit in mem-
ory plus at least 1 additional deficit in another domain was
required); (3) nonamnestic MCI single domain (naMCI-
SD: a deficit in verbal fluency, language, visuospatial skills,
speed of mental processing, or executive function was
required without a memory deficit); (4) nonamnestic MCI
multiple domains (naMCI-MD: deficits in 2 or more do-
mains other than memory were required) [3].2.7. Statistical analysis
Continuous variables were expressed as mean and SD,
and categorical variables as frequencies. The student t test
or one-way analysis of variance was used for comparisons
for continuous variables. The Chi-square test was used for
comparisons of categorical variables.
Annual conversion rate to dementia or reversion rate to
cognitive normal was calculated as the number of incident
dementia or cognitive normal cases occurring during the
follow-up period divided by the cumulative follow-up period
of all participants and described as “per 100 person-years.”
Kaplan–Meier survival analysis was used to estimate the cu-
mulative conversion rate to dementia, or the cumulative
reversion rate to cognitive normal by the follow-up period.
The log-rank test was used to compare rate estimates within
different subgroups.
We used the Cox proportional hazards regression model
of multivariate analysis to explore the predictors for the pro-
gression from MCI to dementia or cognitive normal during
the follow-up period. The covariates of multivariate analysis
were age, gender, education, APOE ε4, and baseline MMSE
score. The individuals remained at a risk as long as they werefree from the outcome during the follow-up period. Adjusted
hazard ratio (HR) along with 95% confidence interval (CI)
was used as the risk or protective measurement for the
outcome of dementia or cognitive normal.
All P values and 95% CIs were estimated in a two-tailed
fashion. Differences were considered to be statistically sig-
nificant at P , .05. Data were analyzed using SPSS 16.0
(SPSS Inc., IL).3. Results
3.1. Baseline characteristics of study participants
We tried to contact 655 individuals with MCI diagnosed
at the baseline, and only 21 were lost contact. Despite 154
ineligible individuals (79 deceased, 58 moved, and 17
were not able to cooperate), 480 were eligible for the
follow-up study. We successfully conducted the interview
for 362 (75%) individuals with MCI diagnosed at the base-
line (Fig. 1).
The baseline characteristics of 655 individuals with MCI
were showed in Table 1. Among them, 289 (44.1%) were
men. Their average age was 74.9 (SD 8.5) years, and
74.8% of them had education background of middle school
or above. The prevalence rates of hypertension, diabetes
mellitus, stroke, and heart disease were 60.0%, 17.9%,
17.9%, and 38.6%, respectively. Smoking and drinking
habits were reported in 11.8% and 7.5%, and APOE ε4 pos-
itive were found in nearly 20% individuals with MCI. At the
baseline, the mean MMSE score was 26.4 (SD, 2.9). The
proportions of MCI subtypes: aMCI-SD, aMCI-MD,
naMCI-SD, and naMCI-MD were 41.5%, 25.2%, 24.3%,
and 9.0%, respectively.
Table 1 also compared the baseline characteristics of in-
dividuals with MCI we interviewed and not interviewed
(including ineligible and refusal individuals). The mean
baseline MMSE score was the only characteristic with sig-
nificant difference between these two groups [interviewed
vs. not interviewed: 26.7 (SD 2.8) vs. 26.1 (SD 3.0),
P5 .009]. There was no significant difference between these
two groups by gender, age, education level, medical history,
life habits, APOE ε4, and MCI subtypes at the baseline.
3.2. Progression of MCI
After the average 3.6 years (1314.2 person-years) of the
follow-up, we diagnosed 79 (21.8%) individuals with de-
mentia and 102 (28.2%) individuals with cognitive normal.
Half of the individuals were still keeping the status with
MCI (Fig. 1).
Table 2 showed that, the conversion rate to dementia
was 6.0 (95% CI: 4.7–7.3) per 100 person-years, whereas
the reversion rate to cognitive normal was 7.8 (95% CI:
6.3–9.2) per 100 person-years. The highest and the second
highest conversion rates were found in individuals with
aMCI-MD [14.2 (95% CI: 10.2–18.2) per 100 person-
years] and in individuals with naMCI-MD [8.7 (95% CI:
Fig. 1. Flow chart of the follow-up study for individuals with mild cognitive impairment diagnosed at the baseline. Abbreviations: MCI, mild cognitive impair-
ment; aMCI, amnestic mild cognitive impairment; naMCI, nonamnestic mild cognitive impairment.
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est and the second highest reversion rates were found in
individuals with aMCI-SD [12.6 (95% CI: 9.9–15.3) per
100 person-years] and in individuals with naMCI-SD
[7.3 (95% CI: 4.5–10.1) per 100 person-years] at the base-
line.
Age-specific conversion rates to dementia were showed
in Fig. 2A. The increasing trend of conversion rates by
increasing age were demonstrated in individuals with four
different MCI subtypes, among which aMCI-MD group
demonstrated the highest conversion rates, from 9.5 per
100 person-years in individuals with 60–69 years old to
18.0 per 100 person-years in individuals aged 80 years
old. Fig. 2B showed negative correlation between the
increasing age and the age-specific reversion rates to cogni-
tive normal in individuals with 4 different MCI subtypes.
The reversion rates decreased more dramatically in individ-
uals with aMCI-SD at the baseline, from 18.9 per 100
person-years in individuals with 60–69 years old to 2.0 per
100 person-years in individuals aged 80 years old.
Fig. 3A showed the Kaplan-Meier curves of accumulative
conversion rate to dementia in individuals with 4 MCI sub-
types by follow-up time. The accumulative conversion rate
of individuals with aMCI-MD increased the most dramati-
cally, second with that of individuals with naMCI-MD,
than that of individuals with other 2 MCI subtypes (Log-
rank test P , .001). The accumulative reversion rate to
cognitive normal of individuals with aMCI-SD increased
most dramatically, second with that of individuals with
naMCI-SD, than that of individuals with other 2 MCI sub-
types by follow-up time (log-rank test, P , .001; Fig. 3B).3.3. Predictors of the MCI progression
Cox multivariate regression model indicated that older
age (HR5 1.09, 95%CI: 1.05–1.14, P, .001) and the lower
MMSE score (HR 5 1.18, 95% CI: 1.06–1.28, P 5 .001) at
baseline were the independent risk predictors to dementia.
Individuals with APOE ε4 positive had more than a 2-fold
greater risk of dementia than did individuals with APOE
ε4 negative (HR 5 2.15, 95% CI: 1.21–3.81, P 5 .009). In-
dividuals with older age (HR 5 0.91, 95% CI: 0.88–0.95,
P , .001) and lower MMSE score (HR 5 0.79, 95% CI:
0.69–0.92, P 5 .002) at baseline were less likely to reverse
to cognitive normal (Table 3).4. Discussion
As the second wave of the Shanghai Aging Study, we
clinically and neuropsychologically evaluated 362 individ-
uals with MCI diagnosed at the baseline, after the average
follow-up time of 3.6 years. The present study demonstrated
that the conversion rate to dementia was 6.0 per 100 person-
years, whereas the reversion rate to cognitive normal was 7.8
per 100 person-years. Individuals with aMCI-MD were the
most risky ones for dementia. Older age, APOE ε4 positive,
and lower MMSE score at baseline were the independent
risk predictors to dementia.
Previous epidemiologic studies of MCI progression in
Asia have been rarely reported. A study in Hongkong re-
cruited 321 community-dwelling Chinese older persons
aged 60 years or older with MCI. At the end of 2-year
follow-up, 51 (15.9%) developed to dementia [8]. A study
Table 1
Baseline characteristics of individuals with MCI, interviewed and not interviewed at the follow-up
Baseline characteristics All individuals with MCI (n 5 655) Interviewed, (n 5 362) Not interviewed, (n 5 293) P value
Gender
Women, n (%) 366 (55.9) 206 (56.9) 160 (54.6) .556
Age, mean 6 SD 74.9 6 8.5 74.4 6 7.8 75.5 6 9.2 .104
Education level
Less than primary school 52 (7.9) 24 (6.6) 28 (9.6) .287
Primary school 113 (17.3) 55 (15.2) 58 (19.8)
Middle school 162 (24.7) 94 (26.0) 68 (23.2)
High school 168 (25.6) 96 (26.5) 72 (24.6)
College and above 160 (24.4) 93 (25.7) 67 (22.9)
Medical history
Hypertension, n (%) 393 (60.0) 214 (59.1) 179 (61.1) .608
Diabetes mellitus, n (%) 117 (17.9) 60 (16.6) 57 (19.5) .339
Stroke, n (%) 117 (17.9) 64 (17.7) 53 (18.1) .892
Heart disease, n (%) 253 (38.6) 136 (37.6) 117 (39.9) .537
Life habits
Smoking, n (%) 77 (11.8) 41 (11.3) 36 (12.3) .704
Drinking, n (%) 49 (7.5) 28 (7.7) 21 (7.2) .784
APOE ε4 positive, n (%) 115 (19.9)* 63 (19.4)y 52 (20.5)z .759
MMSE, mean 6 SD 26.4 6 2.9 26.7 6 2.8 26.1 6 3.0 .009
MCI type
aMCI-SD, n (%) 272 (41.5) 156 (43.1) 116 (39.6) .422
aMCI-MD, n (%) 165 (25.2) 82 (22.7) 83 (28.3)
naMCI-SD, n (%) 159 (24.3) 91 (25.1) 68 (23.2)
naMCI-MD, n (%) 59 (9.0) 33 (9.1) 26 (8.9)
Abbreviations: MCI, mild cognitive impairment; aMCI-SD, amnestic mild cognitive impairment single domain; aMCI-MD, amnestic mild cognitive impair-
ment multiple domains; naMCI-SD, non-amnestic mild cognitive impairment single domain; naMCI-MD, non-amnestic mild cognitive impairment multiple
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or older) with type 2 diabetes mellitus (T2DM-MCI) and
585 participants without diabetes for 5 years. The conver-
sion rate of T2DM-MCI and MCI without diabetes to
dementia were 8.43 (95% CI: 7.96–8.92) per 100 person-
years and 3.86 (95% CI: 2.18–5.56) per 100 person-years
[9]. Another study surveyed elderly aged 65 years or older
in an Arab community in Israel. Of the 231 subjects with
MCI that were re-examined after 1 year, 68 (23%) con-
verted to dementia, including 65 AD cases [10]. These
studies, however, were either with short follow-up period
or with vague diagnosis based on insufficient neuropsycho-
logical tests (e.g., MMSE only). Additionally, none of
these studies investigated the progression of different
MCI subtypes.
The Shanghai Aging Study was an epidemiologic study
conducted in China with a study design, operational proce-
dures, and MCI diagnostic criteria similar to most cohort
studies in developed countries, most of which established
20 years ago. It is also the largest study in which all partic-
ipants were evaluated by comprehensive in-person assess-
ments. The progression data of MCI and its four subtypes
from the current prospective follow-up can be compared
with those from existing population-based cohort studies
in developed countries.The follow-up survey of the Italian Longitudinal Study on
Aging found a progression rate of 3.8 (95% CI: 2.3–6.2) per
100 person-years among 139 individuals (65 to 84 years old)
with MCI at baseline, with a 3.5-year follow-up [22]. The
Monongahela Valley Independent Elders Survey found
27% of 40 persons with MCI at the first assessment devel-
oped to dementia over the next 10 years. Over each 2-year
interval, MCI persons showed increased risk of dementia
with OR 5 3.9 [23]. Different MCI subtypes likely differ
in etiology and eventual outcome [21]. Studies reporting
progression of MCI subtypes are still few. The Leipzig Lon-
gitudinal Study of the Aged in Germany examined a commu-
nity sample of 980 dementia-free individuals aged 75 years
or older. After 6 years of observation, 66 (40.2%) partici-
pants with MCI at baseline converted to dementia. The
proportions of participants with aMCI-SD, aMCI-MD,
naMCI-SD, and naMCI-MD at baseline who converted to
dementia were 43.6%, 53.2%, 33.9%, and 21.1, respectively
[11]. Among community-dwelling residents aged65 years
residing in Northern Manhattan, after a mean duration of
follow-up of 4.7 years, the conversion rate from aMCI to
AD was 7.4 (95% CI: 5.7–9.2) per 100 person-years, and
from naMCI to AD was 4.1 (3.1–5.1) per 100 person-
years. Participants with aMCI-MD had a higher relative
risk (RR) for incident AD than those with aMCI-SD
Fig. 2. Annual conversion rate from MCI to dementia (A) and reversion
rate from MCI to cognitive normal (B) in individuals with different age
groups. Abbreviations: MCI, mild cognitive impairment; aMCI-SD,
amnestic mild cognitive impairment single domain; aMCI-MD,
amnestic mild cognitive impairment multiple domains; naMCI-SD,
nonamnestic mild cognitive impairment single domain; naMCI-MD, non-
amnestic mild cognitive impairment multiple domains.
Table 2





n Person-years n Rate, per 100 person-years (95%CI) n Rate, per 100 person-years (95%CI)
MCI 362 1314.2 79 6.0 (4.7–7.3) 102 7.8 (6.3–9.2)
aMCI 238 859.7 59 6.9 (5.2–8.6) 77 9.0 (7.1–10.9)
aMCI-SD 156 564.1 17 3.0 (1.6–4.4) 71 12.6 (9.9–15.3)
aMCI-MD 82 295.6 42 14.2 (10.2–18.2) 6 2.0 (0.4–3.6)
naMCI 124 454.5 20 4.4 (2.5–6.3) 25 5.5 (3.4–7.6)
naMCI-SD 91 328.4 9 2.7 (1.0–4.5) 24 7.3 (4.5–10.1)
naMCI-MD 33 126.1 11 8.7 (3.8–13.7) 1 0.8 (20.8 to 2.3)
Abbreviations: MCI, mild cognitive impairment; aMCI-SD, amnestic mild cognitive impairment single domain; aMCI-MD, amnestic mild cognitive impair-
ment multiple domains; naMCI-SD, non-amnestic mild cognitive impairment single domain; naMCI-MD, non-amnestic mild cognitive impairment multiple
domains.
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Youghiogheny Healthy Aging Team study reported the 1-
year outcomes of MCI among individuals aged 65 years or
more. Progression to severe cognitive impairment ranged
from 1.1% for naMCI-SD to 19.8% for aMCI-MD. Rever-
sion to cognitively normal ranged from 6.3% for aMCI-
MD to 53.4% for naMCI-SD [13]. The Sydney Memory
and Ageing Study reported that at 2-year follow-up, 4.8%
of 320 participants with baseline MCI (aged 70 to 90 years)
progressed to dementia. The 2-year rate of progression from
MCI at baseline to dementia was 4.8%, being highest for
aMCI-MD (9.1%) [14]. Neuropsychological characteriza-
tion of elderly persons without dementia provides valuable
information about prognosis. Knopman et al quantitated
risk of progression to dementia over the following 6 years
in elderly persons without dementia from the Framingham
Heart Study and Mayo Clinic Study of Aging, aged 70 to
89 years at enrollment. Baseline cognitive status was defined
by performance in 4 domains derived from batteries of neu-
ropsychological tests. Dementia risks were higher for am-
nestic profiles than for nonamnestic profiles and for
multidomain compared with single-domain profiles [24].
Our data are consistent with those from the above-
mentioned studies, indicating that memory impairments
and impairments in multiple domains lead to greater pro-
gression and less improvement of cognitive function.
Previous community-based studies also reported the pre-
dictors of MCI progression, e.g., older age, shorter years of
school, depression, with history of diabetes or stroke, Afri-
can Americans and Hispanic, and baseline MMSE score
[8,11–14,22–24]. Other predictors were reported mostly
from hospital-based studies, such as female gender [25],
APOE genotype [26], white matter hyperintensities [27],
lifestyle-related disease (hypertension, type II diabetes mel-
litus, and lipid abnormality) [28], high plasma C-reactive
protein level [29], orthostatic blood pressure behavior [30],
and unstable body mass index [31]. Our study explored the
older age, APOE ε4 allele positive and low MMSE score
at baseline, but not the gender and education years, werethe independent risk predictors to dementia. We also found
that participants with older age and lower MMSE score
were less likely to revert to cognitive normal. Other factors
may potentially impact the results but need further investiga-
tion.
There are some limitations in the present study. First,
although the interviewed subjects were participants with
Fig. 3. Cumulative conversion rate fromMCI to dementia (A) and cumulative reversion rate fromMCI to cognitive normal (B) in individuals with 4 MCI sub-
types. Abbreviations: MCI, mild cognitive impairment; aMCI-SD, amnestic mild cognitive impairment single domain; aMCI-MD, amnestic mild cognitive
impairment multiple domains; naMCI-SD, nonamnestic mild cognitive impairment single domain; naMCI-MD, nonamnestic mild cognitive impairment mul-
tiple domains.
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there were no statistically difference between interviewed
and not interviewed groups for most of the baseline
characteristics, the selection bias still could not be avoided.Participants without interview had lower MMSE score at the
baseline and more could convert to dementia since lower
MMSE score was a risk predictor for later dementia. Thus,
the conversion rate in our study may be underestimated.
Table 3
Predictors and hazard ratios for MCI progressed to dementia or cognitive normal by Cox regression model
Dementia as the outcome Cognitive normal as the outcome
HR (95% CI) P value HR (95% CI) P value
Gender (women) 0.94 (0.54–1.63) .823 0.75 (0.48–1.17) .206
Baseline age (increasing) 1.09 (1.05–1.14) ,.001 0.91 (0.88–0.95) ,.001
Education year (increasing) 1.06 (0.99–1.13) .090 1.00 (0.93–1.07) .913
Baseline MMSE (decreasing) 1.18 (1.06–1.28) .001 0.79 (0.69–0.92) .002
APOE ε4 positive 2.15 (1.21–3.81) .009 1.16 (0.67–1.98) .602
Abbreviations: MCI, mild cognitive impairment; MMSE, mini-mental state examination; APOE, apolipoprotein; HR, hazard ratio.
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up study because of death and moving to nursing homes or
institutions, and this also might have led to the underestima-
tion of the conversion rate. Second, we could not distinguish
subtypes of dementia because most of the dementia cases did
not take the CT/MRI examination. Documented stroke his-
tory could be useful but not sufficient for the accurate diag-
nosis of the dementia subtype. Third, considering the related
small sample size and the goodness of fit for the statistical
analysis model, we could not put other factors, such as
mood, chronic diseases, and life habits, as potential con-
founders into the multivariate Cox regression model,
although these data have been collected at the baseline.
Finally, results from the present study cannot be generalized
to the whole Chinese population, because our study cohort
has higher educational attainment than that in the general
population in China (50% vs. 26%,  high school) [32],
and our findings may underestimate the conversion rate in
China as a whole.
Currently in China, conservatively estimated based on
our previous and present study results, there are at least
42,400,000 elderly aged 60 years or older living with
MCI; and 2,500,000 of them progress to dementia every
year, which brings the great burden to the family and society.
Further prospective studies with larger sample size and
longer follow-up period are urgently needed in China to
examine other risk and protective predictors to seek proper
interventions for cognitive decline in the increasing aging
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1. Systematic review: We searched PubMed for litera-
ture studies reporting the progression of mild cogni-
tive impairment (MCI) in different ethnic
populations over the last 20 years. Previous data
from Chinese population can hardly be compared
to those from Western studies due to differences in
design, operational procedures, and diagnostic
criteria.
2. Interpretation: This is the first community-based
prospective study conducted in China that used
comparable diagnostic procedures and MCI defini-
tions to most cohort studies in developed countries.
We documented the progression of MCI and its four
subtypes by clinically and neuropsychologically
evaluating individuals with MCI diagnosed at the
baseline.
3. Future directions: Community-based prospective
studies with larger sample size and longer follow-up
in China are urgently needed to: (A) examine other
risk and protective predictors; (B) explore the syn-
ergetic of various factors; and (C) seek proper in-
terventions for cognitive decline in the increasing
aging population.References
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